Technology | Implantable Cardiac Monitor (ICM) | May 09, 2018

FDA Clears Implantable Heart Attack Warning Device

AngelMed Guardian System monitors a patient's heart's electrical activity for changes that may indicate the heart is not getting enough oxygen

The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack.

 The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack. 

The Angel Medical Systems' AngelMed Guardian System system components.

The Angel Medical Systems' AngelMed Guardian System system components.

 May 9, 2018 — The U.S. Food and Drug Administration (FDA) said it recently granted market clearance for Angel Medical Systems' AngelMed Guardian System, an implantable cardiac monitor intended to detect and alert patients of a potential heart attack. 

The system consisting of three components: an implantable medical device (IMD), an external device (EXD) and the programmer collecting and storing information about the patient's heart electrical activity. The IMD, which monitors the heart's electrical activity (electrograms) and alerts a patient with vibrations if it detects a potential heart attack. The EXD alerts the patient of an potential heart attack with alarms and lights letting the patient know to seek medical attention. Patients must have this part of the system with them in order to be alerted. The programmer collects and stores information from the IMD about the patient's heart electrical activity. The doctor can use this information to determine the best treatment option. The doctor can also use the programmer to configure the adjustable settings in the IMD.

The Guardian System monitors a patient's heart's electrical activity for changes that may indicate the heart is not getting enough oxygen and there is a potential for a heart attack. If the device detects those changes, the IMD will vibrate, and the EXD will flash light and alerts the patient to seek medical attention.

The system is indicated for use in patients who have had prior acute coronary syndrome (ACS) events (heart attack and unstable angina) and who remain at high risk for recurrent ACS events. The Guardian System's alarm is intended to alert patients to seek medical care when there is a change in the patient's heart's electrical activity that could be indicative of a heart attack.

The IMD of the AngelMed Guardian System should not be implanted in patients with cognitive impairment that would prevent recognition of alarms, patients who cannot feel the vibration from the IMD, or patients with an implanted pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy devices. It is also contraindicated for patients where a pacemaker lead cannot be placed safely.

Read the FDA approval letter.

Read the summary of safety and effectivness from the FDA.

Related Content

HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init